Staff Profile

I am Visiting Senior Lecturer, Institute of Translational and Clinical Research, University of Newcastle upon Tyne. I read Biochemistry and Physiology in Newcastle, then Medicine at the same University. I trained in Endocrinology, Internal Medicine and Diabetes in Newcastle, Glasgow and Edinburgh. I obtained my MD thesis with commendation from the University of Newcastle.

 My clinical and research interests are in thyroid diseases and in optimising delivery of care to patients with endocrine diseases. 

I am author of a book "Seeking Thyroid Truths: a guide for the curious, published in September 2024. The book is intended for patients, the public and healthcare workers interested in the thyroid: https://link.springer.com/book/10.1007/978-3-031-58287-5

Google scholar: Click here.

SCOPUS: Click here.

I teach endocrinologists at international levels through teaching courses organised by professional bodies such as the European Group on Graves' Orbitopathy and the European Society of Endocrinology

My research focus is in thyroid diseases. I am a member of the European Group on Graves' Orbitopathy, a consortium engaged in multicentre clinical trials on Graves' orbitopathy.

• Articles

  • Lafontaine N, Brown SJ, Perros P, Papini E, Nagy EV, Attanasio R, Hegedus L, Walsh JP. Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia. Clinical Endocrinology 2024, 100(5), 477-485.
  • Negro R, Zarkovic M, Attanasio R, Hegedus L, Nagy EV, Papini E, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Ciric J, Cohen CA, Diez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, Fuhrer D, Galofre JC, Hakala T, Jan J, Kopp P, Krebs M, Krsek M, Kuzma M, Leenhardt L, Luchytskiy V, Puga FM, McGowan A, Melo M, Metso S, Moran C, Morgunova T, Niculescu DA, Peric B, Planck T, Poiana C, Robenshtok E, Rosselet PO, Ruchala M, Riis KR, Shepelkevich A, Tronko M, Unuane D, Vardarli I, Visser E, Vryonidou A, Younes YR, Perros P. Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey). Clinical Endocrinology 2024, (ePub ahead of Print).
  • Galofre JC, Diez JJ, Attanasio R, Nagy EV, Negro R, Papini E, Perros P, Zarkovic M, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Dobnig H, Fadeyev V, Field BCT, Fliers E, Fuhrer D, Hakala T, Jiskra J, Kopp P, Krebs M, Krsek M, Kuzma M, Lantz M, Lazurova I, Leenhardt L, Luchytskiy V, Puga FM, McGowan A, Metso S, Moran C, Morgunova T, Niculescu DA, Peric B, Planck T, Poiana C, Robenshtok E, Rosselet PO, Ruchala M, Riis KR, Shepelkevich A, Tronko M, Unuane D, Vardarli I, Visser WE, Vryonidou M, Younes YR, Hegedus L. Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration. Journal of Endocrinological Investigation 2024, epub ahead of print.
  • Papini E, Attanasio R, Zarkovic M, Nagy EV, Negro R, Perros P, Galofre JC, Cohen CA, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Ciric J, Diez JJ, Dobnig H, Fadeyev V, Field BCT, Fuhrer-Sakel D, Hakala T, Jiskra J, Kopp PA, Krebs M, Krsek M, Lantz M, Lazurova I, Leenhardt L, Luchytskiy V, Puga FM, McGowan A, Melo M, Metso S, Moran C, Morgunova T, Niculescu DA, Peric B, Planck T, Robenshtok E, Rosselet PO, Ruchala M, Riis KR, Shepelkevich A, Tronko M, Unuane D, Vardarli I, Visser WE, Vryonidou A, Younes YR, Hegedus L. Thyroid hormones for euthyroid patients with simple goiter growing over time: a survey of European thyroid specialists. Endocrine 2024, epub ahead of print.
  • Attanasio R, Zarkovic M, Papini E, Nagy EV, Negro R, Perros P, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Ciric J, Diez JJ, Dobnig H, Fadeyev V, Field BC, Fliers E, Fuhrer-Sakel D, Galofre JC, Hakala T, Jiskra J, Kopp PA, Krebs M, Krsek M, Kuzma M, Lantz M, Lazurova I, Leenhardt L, Luchytskiy V, Marques Puga F, McGowan A, Metso S, Moran C, Morgunova T, Niculescu DA, Peric B, Planck T, Poiana C, Robenshtok E, Rosselet PO, Ruchala M, Riis KR, Shepelkevich A, Tronko MD, Unuane D, Vardarli I, Visser WE, Vryonidou A, Younes YR, Hegedus L. Patients' Persistent Symptoms, Clinician Demographics, and Geo-Economic Factors Are Associated with Choice of Therapy for Hypothyroidism by European Thyroid Specialists: The "THESIS" Collaboration. Thyroid 2024, 34(4), 429-441.
  • Hegedus L, Van Der Feltz-Cornelis CM, Papini E, Nagy EV, Weetman AP, Perros P. Medically not yet explained symptoms in hypothyroidism. Nature Reviews Endocrinology 2024, epub ahead of print.
  • Younes YR, Perros P, Hegedus L, Papini E, Nagy EV, Attanasio R, Negro R, Field BCT. Use of thyroid hormones in hypothyroid and euthyroid patients: A THESIS questionnaire survey of UK endocrinologists. Clinical Endocrinology 2023, 98(2), 238-248.
  • Mustafa M, Ali E, McGowan A, McCabe L, Hegedus L, Attanasio R, Nagy EV, Papini E, Perros P, Moran C. Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A THESIS questionnaire survey of members of the Irish Endocrine Society. Irish Journal of Medical Science 2023, 192, 2179-2187.
  • Cassemiro JF, Ilera V, Batalles S, Reyes A, Nagy EV, Papini E, Perros P, Hegedus L, Ramos HE. Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS). Thyroid Research 2023, 16, 40.
  • Nedeljkovic-Beleslin B, Attanasio R, Hegedus L, Nagy EV, Negro R, Papini E, Perros P, Ciric J, Zarkovic M. Use of thyroid hormones in hypothyroid and euthyroid patients – a THESIS questionnaire survey of Serbian physicians. Srpski Arhiv za Celokupno Lekarstvo 2023, 150(11-12), 667-674.
  • Azizi F, Abdi H, Mehran L, Perros P, Masoumi S, Amouzegar A. Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine. Endocrine Practice 2023, 29(4), 240-246.
  • Perros P, Zarkovic M, Pearce SH, Razvi S, Kolli H, Dickinson AJ. Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease. American Journal of Ophthalmology 2023, 252, 94-100.
  • Perros P, Nagy EV, Papini E, Van Der Feltz-Cornelis CM, Weetman AP, Hay HA, Abad-Madronero J, Tallett AJ, Bilas M, Lakwijk P, Poots AJ, Hegedus L. Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey. Thyroid 2023, 33(8), 927-939.
  • Zarkovic M, Attanasio R, Nagy EV, Negro R, Papini E, Perros P, Cohen CA, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu M-C, Ciric J, Diez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, Frolich JS, Fuhrer D, Galofre JC, Hakala T, Jiskra J, Kopp P, Krebs M, Krsek M, Kuzma M, Lantz M, Lazurova I, Leenhardt L, Luchytskiy V, McGowan A, Melo M, Metso S, Moran C, Morgunova T, Mykola T, Beleslin BN, Niculescu DA, Peric B, Planck T, Poiana C, Puga FM, Robenshtok E, Rosselet P, Ruchala M, Riis KR, Shepelkevich A, Unuane D, Vardarli I, Visser WE, Vrionidou A, Younes YR, Yurenya E, Hegedus L. Characteristics of specialists treating hypothyroid patients: the “THESIS” collaborative. Frontiers in Endocrinology 2023, 14, 1225202.
  • Burlacu M-C, Attanasio R, Hegedus L, Nagy EV, Papini E, Perros P, Sawadogo K, Bex M, Corvilain B, Daumerie C, Decallonne B, Gruson D, Lapauw B, Reyes RM, Petrossians P, Poppe K, Van den Bruel A, Unuane D. Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey. Thyroid Research 2022, 15, 3.
  • Berta E, Lengyel IM, Hegedus L, Papini E, Perros P, Negro R, Attanasio R, Nagy VE, Bodor M. Use of thyroid hormones in hypothyroid and euthyroid patients. A THESIS questionnaire survey of Hungarian physiciansPajzsmirigyhormon-kezelési szokások Magyarországon. A THESIS kérdoíves felmérés eredményei. Orvosi Hetilap 2022, 163(12), 463-472.
  • Galofre JC, Attanasio R, Hegedus L, Nagy E, Negro R, Papini E, Perros P, Diez JJ. Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire surveyUso de la hormona tiroidea en pacientes hipotiroideos y sujetos eutiroideos en España. Endocrinologia, Diabetes y Nutricion 2022, 69(7), 520-529.
  • Ayvaz G, Akarsu E, Attanasio R, Hegedus L, Nagy EV, Papini E, Perros P. The Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A THESIS* Questionnaire Survey of Turkish Physicians. Turkish Journal of Endocrinology and Metabolism 2022, 26(2), 85-91.
  • Perros P, Hegedus L, Nagy EV, Papini E, Hay HA, Abad-Madronero J, Tallett AJ, Bilas M, Lakwijk P, Poots AJ. The Impact of Hypothyroidism on Satisfaction with Care and Treatment and Everyday Living: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey. Thyroid 2022, 32(10), 1158-1168.
  • Buffet C, Belin L, Attanasio R, Negro R, Hegedus L, Nagy EV, Papini E, Perros P, Leenhardt L. Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in FrancePratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens : un tableau détaillé des résultats du sondage THESIS en France. Annales d'Endocrinologie 2022, 83(1), 27-34.
  • Perros P, Basu A, Boelaert K, Dayan C, Vaidya B, Williams GR, Lazarus JH, Hickey J, Drake WM, Crown A, Orme SM, Johnson A, Ray DW, Leese GP, Jones TH, Abraham P, Grossman A, Rees A, Razvi S, Gibb FW, Moran C, Madathil A, Zarkovic MP, Plummer Z, Jarvis S, Falinska A, Velusamy A, Sanderson V, Pariani N, Atkin SL, Syed AA, Sathyapalan T, Nag S, Gilbert J, Gleeson H, Levy MJ, Johnston C, Sturrock N, Bennett S, Mishra B, Malik I, Karavitaki N. Post-radioiodine Graves' management: the PRAGMA study. Clinical Endocrinology 2022, 97(5), 664-675.
  • Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid 2022, 32(12), 1439-1470.
  • van der Feltz-Cornelis CM, Sweetman J, Edwards M, Gall N, Gilligan J, Hayle S, Kaul A, Moriarty AS, Perros P, Sampford J, Smith N, Elfeddali I, Varley D, Gower J. Identifying the top research priorities in medically not yet explained symptoms (MNYES): a James Lind Alliance priority setting partnership. BMJ open 2022, 12(7), e061263.
  • Zarkovic M, Perros P, Ciric J, Beleslin B, Stojanovic M, Stojkovic M, Miletic M, Janic T. Health care access of thyroid disease patients in Serbia during the COVID-19 pandemic. Journal of Endocrinological Investigation 2022, 45, 1521–1526.
  • Vardarli I, Brandenburg T, Hegedus L, Attanasio R, Nagy E, Papini E, Perros P, Weidemann F, Herrmann K, Fuhrer D. A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Collaborative. Experimental and Clinical Endocrinology and Diabetes 2022, 130(09), 577-586.
  • Planck T, Lantz M, Perros P, Papini E, Attanasio R, Nagy EV, Hegedus L. Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society. Frontiers in Endocrinology 2021, 12, 795111.
  • Riis KR, Frolich JS, Hegedus L, Negro R, Attanasio R, Nagy EV, Papini E, Perros P, Bonnema SJ. Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS questionnaire survey of members of the Danish Endocrine Society. Journal of Endocrinological Investigation 2021, 44, 2435-2444.
  • Mitchell AL, Hegedus L, Zarkovic M, Hickey JL, Perros P. Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. Clinical Endocrinology 2021, 94(3), 513-520.
  • Shepelkevich AP, Dydyshka YV, Yurenya EV, Lоbashova VL, Attanasio R, Hegedus L, Nagy E, Negro R, Papini E, Perros P. Features of the use of synthetic analogues of thyroid hormones: а 2020 THESIS* questionnaire survey of members of the Belarusian Public Medical Association of Endocrinology and Metabolism. Problemy endokrinologii 2021, 68(1), 18-26.
  • Zarkovic M, Wiersinga W, Perros P, Bartalena L, Donati S, Okosieme O, Morris D, Fichter N, Lareida J, Daumerie C, Burlacu M-C, Kahaly GJ, Pitz S, Beleslin B, Ciric J, Ayvaz G, Konuk O, Toruner FB, Salvi M, Covelli D, Curro N, Hegedus L, Brix T. Antithyroid drugs in Graves’ hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves’ orbitopathy during treatment. Journal of Endocrinological Investigation 2021, 44, 371-378.
  • Pavlatou MG, Zarkovic M, Hegedus L, Priestley J, McMullan C, Perros P. A survey on the psychological impact and access to health care of thyroid patients during the first SARS-COV-2 lockdown. Clinical Endocrinology 2021, 96(6), 869-877.
  • Negro R, Attanasio R, Nagy EV, Papini E, Perros P, Hegedus L. Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; The 2019 Italian Survey. European Thyroid Journal 2020, 9, 25-31.
  • Lane LC, Cheetham TD, Perros P, Pearce SHS. New Therapeutic Horizons for Graves' Hyperthyroidism. Endocrine Reviews 2020, 41(6), bnaa022.
  • Perros P, Mason D, Pearce M, Pearce SHS, Chandler R, Mallick UK. Differentiated thyroid cancer mortality by disease stage in northern England. Clinical Endocrinology 2020, 93(1), 61-66.
  • Perros P, Zarkovic MP, Panagiotou GC, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi AM, Nardi M, Brix TH, Covelli D, Daumerie C, Eckstein AK, Fichter N, Ciric S, Hegedus L, Kahaly GJ, Konuk O, Lareida JJ, Okosieme OE, Leo M, Mathiopoulou L, Clarke L, Menconi F, Morris DS, Orgiazzi J, Pitz S, Salvi M, Muller I, Knezevic M, Wiersinga WM, Curro N, Dayan CM, Marcocci C, Marino M, Moller L, Pearce SH, Toruner F, Bernard M, Perros P, Lareida JJ. Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation 2020, 43, 1717-1722.
  • Pearce SHS, Dayan C, Wraith DC, Barrell K, Olive N, Jansson L, Walker-Smith T, Carnegie C, Martin KF, Boelaert K, Gilbert J, Higham CE, Muller I, Murray RD, Perros P, Razvi S, Vaidya B, Wernig F, Kahaly GJ. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid 2019, 29(7), 1003-1011.
  • Lee V, Avari P, Williams B, Perros P, Dayan C. A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye 2019, 34(11), 1662–1671.
  • Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Horsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-Related Cancer 2018, 25(3), 309-322.
  • Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Fuhrer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marino M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, Ayvaz G, Baldeschi L, Boborides K, Boschi A, Brix TH, Clarke L, Dayan C, Daumerie C, Dickinson AJ, Fichter N, Hegedus L, Konuk O, Krassas GE, Lane C, Lazarus J, Morris DS, Mourits M, Nardi M, Neoh C, Orgiazzi J, Pearce SHS, von Arx G, Zarkovic M. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. The Lancet Diabetes and Endocrinology 2018, 6(4), 287-298.
  • MacAuley M, Shawgi M, Ali T, Curry A, Howe K, Howell E, Jefferson E, James A, Perros P, Petrides GS. Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. Nuclear Medicine Communications 2018, 39(9), 834-838.
  • Wong Y, Dickinson J, Perros P, Dayan C, Veeramani P, Morris D, Foot B, Clarke L. A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. Eye 2018, 32(10), 1555-1562.
  • Gan EH, Mitchell AL, Plummer R, Pearce S, Perros P. Tremelimumab-Induced Graves Hyperthyroidism. European Thyroid Journal 2017, 6(3), 167-170.
  • Mitchell AL, Hickey J, Vaidya B, Mason R, Ajjan R, Zammitt N, Perros P, Dayan C, on behalf of TEAMeD. Raising awareness of Graves' orbitopathy with early warning cards. Clinical Endocrinology 2017, 87(6), 853-859.
  • Mellington FE, Dayan CM, Dickinson AJ, Hickey JL, MacEwen CJ, McLaren J, Perros P, Rose GE, Uddin J, Vaidya B, Foley P, Lazarus JH, Mitchell A, Ezra DG, on behalf of The Thyroid Eye Disease Amsterdam Declaration Implementation Group (TEAMeD). Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit 2017, 36(3), 159-169.
  • Mitchell AL, Devine K, Lal V, Galloway P, House M, White K, Watson J, Parry S, Miller M, Morris M, James RA, Perros P, Pearce SHS, Quinton R. Improving the prehospital safety of steroid-dependent patients in northern England: A hospital-initiated ambulance service registration pathway. Clinical Endocrinology 2017, 87(6), 881-882.
  • Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marino M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curro N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?. Journal of Endocrinological Investigation 2017, 40(5), 547-553.
  • Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy. European Thyroid Journal 2016, 5(1), 9-26.
  • Evans C, Tennant S, Perros P. Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scandinavian Journal of Clinical & Laboratory Investigation 2016, 76(sup245), S119-S123.
  • Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME, SYMNET Study Grp. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease 2016, 48(5), 552-558.
  • Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology and Otology 2016, 130(S2), S150-S160.
  • Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, Boschi A, Bournaud C, Brix TH, Covelli D, Ciric S, Daumerie C, Eckstein A, Fichter N, Fuhrer D, Hegedus L, Kahaly GJ, Konuk O, Lareida J, Lazarus J, Leo M, Mathiopoulou L, Menconi F, Morris D, Okosieme O, Orgiazzi J, Pitz S, Salvi M, Vardanian-Vartin C, Wiersinga W, Bernard M, Clarke L, Curro N, Dayan C, Dickinson J, Knezevic M, Lane C, Marcocci C, Marino M, Moller L, Nardi M, Neoh C, Pearce S, von Arx G, Toruner FB. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology 2015, 99(11), 1531-1535.
  • Perros P, Dayan CM, Dickinson AJ, Ezra D, Estcourt S, Foley P, Hickey J, Lazarus JH, MacEwen CJ, McLaren J, Rose GE, Uddin J, Vaidya B. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical Medicine 2015, 15(2), 173-178.
  • Perros P. Hypothyroxinemia, Hyperthyrotropinemia, and Radioiodine: Partners in Crime Against Graves Orbitopathy?. AACE Clinical Case Reports 2015, 1(2), e145-e146.
  • Mitchell AL, Goss L, Mathiopoulou L, Morris M, Vaidya B, Dickinson AJ, Quinn A, Dayan C, McLaren J, Hickey JL, Lazarus JH, Rose GE, Foley P, MacEwen CJ, Perros P. Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. Journal of Clinical Endocrinology & Metabolism 2015, 100(3), E458-E462.
  • Gan EH, MacArthur K, Mitchell AL, Hughes BA, Perros P, Ball SG, James RA, Quinton R, Chen S, Furmaniak J, Arlt W, Pearce SHS. Residual Adrenal Function in Autoimmune Addison's Disease: Improvement After Tetracosactide (ACTH_1-24) Treatment. Journal of Clinical Endocrinology and Metabolism 2014, 99(1), 111-118.
  • Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology 2014, 25(3), 146-154.
  • Robinson J, Richardson M, Hickey J, James A, Pearce SH, Ball SG, Quinton R, Morris M, Miller M, Perros P. Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. European Thyroid Journal 2014, 3(4), 245-251.
  • Di Maria C, Allen J, Dickinson J, Neoh C, Perros P. Novel Thermal Imaging Analysis Technique for Detecting Inflammation in Thyroid Eye Disease. Journal of Clinical Endocrinology & Metabolism 2014, 99(12), 4600-4606.
  • Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR. Guidelines for the management of thyroid cancer. Clinical Endocrinology 2014, 81(s1), 1-122.
  • Mitchell AL, Gan EH, Morris M, Johnson K, Neoh C, Dickinson AJ, Perros P, Pearce SHS. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. Clinical Endocrinology 2013, 79(3), 437-442.
  • Yang MG, Perros P. Management plan and delivery of care in Graves' ophthalmopathy patients. Best Practice & Research Clinical Endocrinology & Metabolism 2012, 26(3), 303-311.
  • Jackson M, Heer R, El-Sherif A, Perros P, Thorpe A. Carcinoid tumour in an ileocystoplasty: A reminder to consider native bowel disease in the reconstructed urinary tract. British Journal of Medical and Surgical Urology 2011, 4(1), 39-41.
  • Perros P. 2009 American Thyroid Association Guidelines on Thyroid Nodules. Clinical Oncology 2010, 22(6), 469-471.
  • Dickinson J, Perros P. Thyroid-Associated Orbitopathy: Who and How to Treat. Endocrinology & Metabolism Clinics of North America 2009, 38(2), 373-388.
  • Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, Von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on the management of GO. Endocrinologia y Nutricion 2008, 55(8), e1-e13.
  • Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology 2008, 158(3), 273-285.
  • Sutherland A, Davies JM, Owen CJ, Vaikkakara S, Walker C, Cheetham TD, James RA, Perros P, Donaldson PT, Cordell HJ, Quinton R, Pearce SHS. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. Journal of Clinical Endocrinology & Metabolism 2007, 92(8), 3338-3341.
  • McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, Hullo AI, Kahaly G, Krassas G, Marcocci C, Marino M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Prummel MF, Sartini MS, Wiersinga WM. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. British Journal of Ophthalmology 2007, 91(4), 455-458.
  • Frew J, Mallick U, Perros P. A patient with asymmetric parotid uptake on a diagnostic iodine-131 scan during thyroid cancer follow-up. Thyroid 2007, 17(8), 801-802.
  • Razvi S, Vaidya B, Perros P, Pearce SHS. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. European Journal of Endocrinology 2006, 154(6), 783-786.
  • Sibal L, Jovanovic A, Agarwal SC, Peaston RT, James RA, Lennard TWJ, Bliss R, Batchelor A, Perros P. Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clinical Endocrinology 2006, 65(2), 186-190.
  • Woods DR, Arun CS, Corris PA, Perros P. Lesson of the week - Cushing's syndrome without excess cortisol. British Medical Journal 2006, 332(7539), 469-470.
  • Woods DR, Arun CS, Corris PA, Perros P. Cushing's syndrome without excess cortisol. British Medical Journal 2006, 332(7539), 469-70.
  • Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G. Clinical assessment of patients with Graves' orbitopathy: The European Group on Graves' orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology 2006, 155(3), 387-389.
  • Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Wiersinga WM. A questionnaire survey on the management of Graves' orbitopathy in Europe. European Journal of Endocrinology 2006, 155(2), 207-211.
  • Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 2005, 28(6), 1431-1437.
  • Hart RH, Kendall-Taylor P, Crombie A, Perros P. Early Response to Intravenous Glucocorticoids for Severe Thyroid-Associated Ophthalmopathy Predicts Treatment Outcome. Journal of Ocular Pharmacology and Therapeutics 2005, 21(4), 328-336.
  • Vaidya B, Shenton BK, Stamp S, Miller M, Baister E, Andrews CD, Dickinson AJ, Perros P, Kendall-Taylor P. Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: Absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy. Thyroid 2005, 15(9), 1073-1078.
  • Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, Pearce SHS. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. Journal of Clinical Endocrinology and Metabolism 2004, 89(11), 5862-5865.
  • Warren RE, Perros P, Nyirenda MJ, Frier BM. Serum thyrotropin is a better predictor of future thyroid dysfunction than thyroid autoantibody status in biochemically euthyroid patients with diabetes: Implications for screening. Thyroid 2004, 14(10), 853-857.
  • Houston FA, Wilson V, Jennings CE, Owen CJ, Donaldson P, Perros P, Pearce SHS. Role of the CD40 locus in Graves' disease. Thyroid 2004, 14(7), 506-509.
  • Sibal L, Ball SG, Connolly V, James RA, Kane P, Kelly WF, Kendall-Taylor P, Mathias D, Perros P, Quinton R, Vaidya B. Pituitary apoplexy: A review of clinical presentation, management and outcome in 45 cases. Pituitary 2004, 7(3), 157-163.
  • Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P. Double-blind, placebo-controlled trial of octreotide Long-Acting Repeatable (LAR) in thyroid-associated ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 2004, 89(12), 5910-5915.
  • Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J, Furmaniak J. A New Assay for Thyrotropin Receptor Autoantibodies. Thyroid 2004, 14(10), 830-835.
  • Phillips AW, Fenwick JD, Mallick UK, Perros P. The impact of clinical guidelines on surgical management in patients with thyroid cancer. Clinical Oncology 2003, 15(8), 485-489.
  • Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazii J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: The first European Group on Graves' Orbitopathy experience. European Journal of Endocrinology 2003, 148(5), 491-495.
  • Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma - Correlation with clinical outcome after 3 years of follow-up. Cancer 2003, 98(1), 41-47.
  • Vaidya B, Oakes EJC, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, Pearce SHS. CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clinical Endocrinology 2003, 58(6), 732-735.
  • Dashora U, Mathias D, James A, Zammit-Maempel I, Perros P. Management of recurrent pituitary cysts with pituitary-nasal drain. Pituitary 2002, 5(4), 225-233.
  • Imrie H, Vaidya B, Perros P, Kelly WF, Toft AD, Young ET, Kendall-Taylor P, Pearce SHS. Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population. Journal of Clinical Endocrinology and Metabolism 2001, 86(2), 626-630.
  • McIntyre EA, Abraha HD, Perros P, Sherwood RA. Serum S-100β protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. Diabetic Medicine 2000, 17(11), 807-809.
  • Perros P, Singh RK, Ludlam CA, Frier BM. Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabetic Medicine 2000, 17(10), 749-751.
  • Mallick UK, Lucraft H, Proud G, Perros P, Fenwick J, Kendall-Taylor P, Johnson S, Lennard TWJ, Ball S, James RA, Douglas F, Weightman DR. Optimizing the management of differentiated thyroid cancer. Clinical Oncology 2000, 6(12), 363-4.
  • Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, Kendall-Taylor P, Pearce SHS. Evidence for a new Graves disease susceptibility locus at chromosome 18q21. American Journal of Human Genetics 2000, 66(5), 1710-1714.
  • Perros P, Frier BM. Evaluation of an on-call diabetes service in a large teaching hospital. Diabetic Medicine 2000, 17(5), 386-389.
  • Herlihy OM, Perros P. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes/Metabolism Research and Reviews 2000, 16(3), 211-216.
  • Vaidya BJ, Imrie H, Geatch D, Perros P, Ball SG, Baylis PH, Carr D, Hurel S, James RA, Kelly WF, Kemp E, Young ET, Weetman A, Kendall-Taylor P, Pearce SHS. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. Journal of Clinical Endocrinology and Metabolism 2000, 85(2), 688-691.
  • Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SHS. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics 1999, 8(7), 1195-1199.
  • Mousa A, Jones S, Toft A, Perros P. Spontaneous rupture of Achilles tendon: missed presentation of Cushing's syndrome. British Medical Journal 1999, 319(7209), 560-561.
  • Gleeson H, Kelly W, Toft A, Dickinson J, Kendall-Taylor P, Fleck B, Perros P. Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy. Thyroid 1999, 9(11), 1115-1118.
  • Pearce SHS, Vaidya BJ, Imrie H, Perros P, Kelly WF, Toft AD, McCarthy MI, Young ET, Kendall-Taylor P. Further evidence for a susceptibility locus on chromosome 20q13.11 in families with dominant transmission of Graves disease. American Journal of Human Genetics 1999, 65(5), 1462-1465.
  • Strachan MWJ, Abraha HD, Sherwood RA, Lammie GA, Deary IJ, Ewing FME, Perros P, Frier BM. Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes - Metabolism: Research and Reviews 1999, 15(1), 5-12.
  • Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P, Pearce SHS. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. The Lancet 1999, 354(9180), 743-744.
  • P. Perros and P. Kendall-Taylor. Natural history of thyroid eye disease. Thyroid 1998, 8, 423-425.
  • P. Kendall-Taylor and P. Perros. Clinical presentation of thyroid associated orbitopathy. Thyroid 1998, 8, 427-428.
  • Perros P, Simpson AJ, Innes JA, Teale JD, McKnight JA. Non-islet cell tumour-associated hypoglycaemia: ¹¹¹In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clinical Endocrinology 1996, 44(6), 727-731.
  • KENDALLTAYLOR P, STEPHENSON A, STRATTON A, PAPIHA SS, PERROS P, ROBERTS DF. DIFFERENTIATION OF AUTOIMMUNE OPHTHALMOPATHY FROM GRAVES HYPERTHYROIDISM BY ANALYSIS OF GENETIC-MARKERS. CLINICAL ENDOCRINOLOGY 1988, 28(6), 601-610.

• Book Chapters

  • Di Maria C, Perros P, Dickinson J, Allen J. Exploratory thermal and laser speckle contrast imaging measurements of eye inflammation in a case of thyroid eye disease. In: Francis Ring, Anna Jung, Janusz Zuber, ed. Infrared Imaging: A Casebook in Clinical Medicine. Institute of Physics Publishing, 2015.
  • Perros P, Bjorgaas MR. Neurological Sequelae of Hypoglycaemia. In: BM Frier, SR Heller and RJ McCrimmon, ed. Hypoglycaemia in Clinical Diabetes: Third Edition. Oxford: John Wiley & Sons Ltd, 2014, pp.305-322.

• Conference Proceedings (inc. Abstracts)

  • Ruszniewski P, Caplin ME, Valle JW, Lombard-Bohas C, Poston G, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Gomez-Panzani E. Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) With Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients With Carcinoid Syndrome (CS): Results From the SymNET Study. In: 7th Annual Meeting of the North American NeuroEndocrine Tumor Society. 2015, Nashville, Tennessee, USA: Lippincott Williams & Wilkins.
  • Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P. Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study. In: 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2015, Barcelona, Spain: Karger.
  • Ruszniewski P, Caplin M, Valle L, Lombard-Bohas D, Poston G, Perros P, Holubec L, Delle Pave G, Smith D, Niccoli P, Maisonobe P, Atlan P. SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts). In: 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2014, Barcelona, Spain: Karger.
  • Ruszniewski PB, Caplin ME, Valle JW, Lombard-Bohas C, Poston GJ, Perros P, Holubec L, Delle Fave G, Smith DM, Niccoli P, Maisonobe P, Atlan P. Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study. In: 2014 Annual Meeting of the American Society of Clinical Oncology. 2014, Chicago, Illinois: American Society of Clinical Oncology.
  • Lunberg-Adams M, James A, Perros P. Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors. In: 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2014, Barcelona, SPAIN: S. Karger AG.
  • Hearn K, Teo L, Bernstone G, Johnson S, Perros P, Manas D, Wright R, James A. Survival of Neuroendocrine Tumor Patients in Newcastle NHS Foundation Trust. In: Neuroendocrinology: 7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2010, Berlin, Germany: S. Karger AG.
  • Teo L, Hearn K, Bernstone G, Wright R, Manus D, Perros P, James A. Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-Indoleacetic acid (5-HIAA) Use in Monitoring Somatostatin Analogue (SSA) Therapy at Newcastle NHS Foundation Trust. In: Neuroendocrinology: 7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 2010, Berlin, Germany: S. Karger AG.
  • Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, Von Arx G, Wiersinga WM. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. In: Thyroid: Annual Meeting of the European Thyroid Association. 2008, Leipzig, Germany: Mary Ann Liebert, Inc. Publishers.
  • Nag S, Perros P, James RA, Ball SG. Rapid blockade with sodium ipodate in the pre-surgical managementof thyrotoxicosis: a retrospective audit. In: 20th Joint Meeting of the British Endocrine Societies. 2001, Belfast, UK.
  • Imrie H, Vaidya B, Perros P, Kelly WF, Toft AD, Young ET, Kendall-Taylor P, Pearce SHS. Genome scanning for Graves' disease susceptibility loci in a UK population. In: Journal of Medical Genetics. 1999, BMJ Group.
  • KENDALLTAYLOR P, PERROS P. CIRCULATING RETROBULBAR ANTIBODIES IN GRAVES OPHTHALMOPATHY. In: ACTA ENDOCRINOLOGICA. 1989.

• Editorials

  • Bukowczan J, Lois KB, Skinner J, Petrides G, James RA, Perros P. Metastatic Midgut Carcinoid in the Myocardium. Clinical Nuclear Medicine 2015, 40(9), E446-E447.
  • Perros P, Dayan CM, Dickinson AJ, Ezra DG, Hickey JL, Hintschisch C, Kahaly G, Lazarus JH, Ludgate M, Bartes B, MacEwen CJ, Mitchell AL, Morris D, O'Connor N, Pearce SH, Rose GE, Salvi M, Wiersinga WM, Williamson A, Thyroid Eye Dis Amsterdam Declarat, European Grp Graves Orbitopathy EU. Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. Thyroid 2015, 25(11), 1181-1184.
  • Perros P, Thyroid Canc Guidelines Update Grp. Introduction to the updated guidelines on the management of thyroid cancer. Clinical Medicine 2007, 7(4), 321-322.
  • Perros P. Thyrotoxicosis and pregnancy. PLOS MEDICINE 2005, 2(12), 1248-1252.
  • Perros P. A 69-year-old female with tiredness and a persistent tan. PLoS Medicine 2005, 2(8), 739-742.
  • Perros P, Mallick UK, Fenwick JD. Radioiodine uptake in normal female breasts and liver of a patient with differentiated thyroid cancer imaged by whole body scanning. Thyroid 2003, 13(5), 511-511.
  • Perros P, Krassas GE. Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose?. Clinical Endocrinology 2002, 56(6), 689-691.
  • Mallick UK, Lucraft H, Proud G, Perros P, Fenwick J, Kendall-Taylor P, Johnson S, Lennard TWJ, Ball S, James RA, Douglas F, Weightman DR. Optimizing the management of differentiated thyroid cancer. Clinical Oncology 2000, 12(6), 363-364.

• Letters

  • Barbar B, Hossen S, Quinton R, James A, Perros P, Pearce S, Napier C, Gan E, Mitchell A, Mamoojee YH. Levothyroxine absorption test: A therapeutic strategy for improving medication adherence. Clinical Endocrinology 2023, 98(5), 741-742.
  • Mitchell AL, Napier C, Asam M, Siddaramaiah N, Heed A, Morris M, Miller M, Perros P, James RA, Ball SG, Pearce SHS, Quinton R. Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform. Clinical Endrocrinology 2014, 81(6), 937-938.
  • Perros P, Weightman DR. Role of serum thyroglobulin measurement in patients with thyroid nodules. Clinical Endocrinology 2003, 59(5), 657.
  • Fenwick JD, Mallick UK, Perros P. I-123 imaging in the follow-up of differentiated thyroid cancer. Clinical Oncology 2001, 13(4), 314-314.
  • Paterakis T, Ebels H, Mallick UK, Proud G, Jones N, Lucraft H, Fenwick J, Weightman D, Kendall-Taylor P, Perros P. Lack of antigenicity of recombinant human thyrotropin after multiple injections in patients with differentiated thyroid cancer. Thyroid 2000, 10(7), 623-623.

• Note

  • Perros P. Managing the burden of incidental FDG-avid thyroid nodules: New consensus statement. Clinical Endocrinology 2024, 100(5), 486-487.

• Reviews

  • Perros P, Hegedus L. Teprotumumab in thyroid eye disease: wonder drug or great divider?. European Thyroid Journal 2023, 12(4), e230043.
  • Bednarczuk T, Attanasio R, Hegedus L, Nagy EV, Negro R, Papini E, Perros P, Ruchala M. Use of thyroid hormones in hypothyroid and euthyroid patients: A THESIS questionnaire survey of Polish physicians: THESIS: Treatment of hypothyroidism in Europe by specialists: An international survey. Endokrynologia Polska 2021, 72(4), 357-365.
  • Perros P, Van Der Feltz-Cornelis C, Papini E, Nagy EV, Weetman AP, Hegedus L. The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clinical Endocrinology 2021, 24, 1294–1324.
  • Perros P, Nirantharakumar K, Hegedüs L. Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death. European Journal of Endocrinology 2021, 184(2), C1-C3.
  • Panagiotou G, Perros P. Asymmetric Graves’ Orbitopathy. Frontiers in Endocrinology 2020, 11, 611845.
  • Perros P. A decade of thyroidology. Hormones 2018, 17(4), 491-495.
  • Perros P, Hegedus L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Curro N, Konuk O, Marino M, Mitchell AL, Stankovic B, Toruner FB, Von Arx G, Zarkovic M, Wiersinga WM. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases 2017, 12(1), 72.
  • Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, Leese G, McCabe C, Perros P, Smith V, Williams G, Vanderpump M. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology 2016, 84(6), 799-808.
  • Evans C, Tennant S, Perros P. Thyroglobulin in differentiated thyroid cancer. Clinica Chimica Acta 2015, 444, 310-317.
  • Lois K, Bukowczan J, Perros P, Jones S, Gunn M, James RA. The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary 2015, 18(4), 568-574.
  • Coulter I, Frewin S, Krassas GE, Perros P. Psychological implications of Graves' orbitopathy. European Journal of Endocrinology 2007, 157(2), 127-131.
  • Kaklamanos M, Perros P. Lesson of the week - Milk alkali syndrome without the milk. British Medical Journal 2007, 335(7616), 397-398.
  • Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine: Related Cancer 2005, 12(1), 49-64.
  • Krassas GE, Perros P. Thyroid disease and male reproductive function. Journal of Endocrinological Investigation 2003, 26(4), 372-380.
  • Mallick, U., Ball, S., Fenwick, ., James, R., Johnson, S., Kendall-Taylor, P., Lennard, T.W.J., Lucraft, H., Proud, G., Perros, P., Weightman, D., Douglas, F. Northern cancer network guidelines for management of thyroid cancer. Clinical Oncology 2000, 12(6), 373-391.
  • PERROS P, KENDALLTAYLOR P. THE PATHOGENESIS OF THYROID-ASSOCIATED OPHTHALMOPATHY. JOURNAL OF ENDOCRINOLOGY 1989, 122(3), 619-624.